Pramodini Medicare Shares Make Modest Debut at ₹120 After 3.87x Subscription

Pramodini Medicare shares made a positive debut on the Indian stock market on Wednesday, 19 August. The stock listed at ₹120 per share on the NSE, representing a premium of 1.69% over its IPO issue price of ₹118. The listing came after the IPO received an overall subscription of 3.87 times.

Pramodini Medicare IPO Listing Details

Pramodini Medicare received SEBI approval for an IPO of around ₹69.04 crore. The issue comprised a fresh issue of ₹63.14 crore along with an offer for sale (OFS) of up to 5,00,400 equity shares with a face value of ₹10 each.

The IPO was offered at a price band of ₹110-₹118 per share. It opened for public subscription on 12 August and closed on 14 August 2026. The share allotment was finalised on 17 August, with refunds scheduled for 18 August and the listing on 19 August.

The IPO received an overall subscription of 3.87 times. The retail investor portion was subscribed 3.49 times, the Qualified Institutional Buyers (QIB) portion 3.66 times, and the Non-Institutional Investors (NII) portion 4.96 times.

First-Day Trading Performance

NSE Listing Price: Pramodini Medicare share price debuted at ₹120 per share, representing a premium of 1.69% over the upper end of the IPO price band of ₹118..

While the stock delivered a positive listing gain, the premium was modest compared with some of the stronger IPO debuts in the market.

Growth Drivers and Challenges

Growth Drivers

Diversified Diagnostic Services: Pramodini Medicare provides diagnostic services across radiology, clinical laboratory and nuclear medicine, giving the company exposure to multiple areas of the healthcare diagnostics segment.

Wide Radiology Portfolio: The company's radiology services include MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, DEXA scans and interventional radiology.

Clinical Laboratory Capabilities: Its laboratory services span haematology, microbiology, immunology, pathology and biochemistry, broadening the range of diagnostic services available to patients and healthcare partners.

Nuclear Medicine Services: Pramodini Medicare also provides nuclear medicine services, including PET-CT, SPECT and nuclear therapy, expanding its presence beyond conventional diagnostic services.

Multiple Operating Models: The company operates diagnostic centres through Public-Private Partnerships (PPP), Private-Private Partnerships (Pvt-Pvt), strategic partnerships with PSUs, standalone diagnostic centres and location-specific agreements.

Investment in Medical Equipment: A portion of the fresh issue proceeds is proposed to be used for purchasing medical equipment for existing and proposed diagnostic centres, supporting the company's diagnostic infrastructure.

Challenges

Moderate Listing Premium: Pramodini Medicare listed at a premium of 1.69% over the issue price, resulting in relatively modest listing gains for IPO allottees.

Capital-intensive Operations: Diagnostic centres require investment in medical equipment and infrastructure, particularly for advanced radiology and nuclear medicine services.

Execution of Expansion Plans: The benefits from investments in existing and proposed diagnostic centres will depend on effective deployment of capital, installation of equipment and utilisation of the expanded infrastructure.

Partnership Dependence: As the company operates through several partnership models, including PPPs, private partnerships and PSU arrangements, the performance of certain operations may depend on maintaining these relationships.

Competitive Healthcare Diagnostics Market: The diagnostics sector includes hospital-based laboratories, standalone diagnostic centres and organised diagnostic chains, making service quality, technology and accessibility important competitive factors.

Utilisation of IPO Proceeds

The company plans to utilise the net proceeds from the fresh issue for:

• Funding capital expenditure for the purchase of medical equipment for existing and proposed diagnostic centres
• General corporate purposes
• Unidentified inorganic acquisitions

Business Overview

Founded in 2000, Pramodini Medicare Limited is a diagnostic services provider operating across radiology, clinical laboratory and nuclear medicine segments.

Its radiology services include MRI, CT scans, X-ray, ultrasound with colour Doppler, mammography, DEXA scans and interventional radiology. Its clinical laboratory services include haematology, microbiology, immunology, pathology and biochemistry, while its nuclear medicine portfolio includes PET-CT, SPECT and nuclear therapy.

Pramodini Medicare operates diagnostic centres through multiple models, including Public-Private Partnerships, Private-Private Partnerships, strategic partnerships with PSUs, standalone diagnostic centres and location-specific agreements.

The IPO, priced in a band of ₹110-₹118 per share, received an overall subscription of 3.87 times. Pramodini Medicare entered the stock market on 19 August at ₹120 per share on the NSE, representing a listing premium of 1.69% over the ₹118 issue price.